



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 183 492
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 85308491.1

(51) Int. Cl. 4: C 07 D 233/58
C 07 D 405/04, A 61 K 31/415

(22) Date of filing: 21.11.85

(30) Priority: 23.11.84 GB 8429578

(72) Inventor: Karjalainen, Arto Johannes
Myllyojantie 13 H 37
SF-90650 Oulu 65(FI)

(43) Date of publication of application:
04.06.86 Bulletin 86/23

(72) Inventor: Virtanen, Raimo Einari
Knaapintie 2-4
SF-21290 Rusko(FI)

(64) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(72) Inventor: Karjalainen, Arja Leena
Tiltiltie 15 C 24
SF-90650 Oulu 65(FI)


(71) Applicant: Farmos-Yhtymä Oy
P.O. Box 425
SF-20101 Turku 10(FI)

(72) Inventor: Kurkela, Kauko Oiva Antero
Keulatie 4
SF-90560 Oulu 56(FI)

(74) Representative: Collier, Jeremy Austin Grey et al,
J.A.Kemp & Co. 14, South Square Gray's Inn
London WC1R 5EU(GB)

(54) Substituted imidazole derivatives and their preparation and use.

(55) The compounds of the formula:




wherein X is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{O}-$, R₁ is H, lower alkyl or lower alkenyl group, OCH₃ or OCH₂CH₃, R₂ is H, CH₃, CH₂CH₃, OCH₃ or OH, R₃ is H, CH₃, CH₂CH₃, OCH₃ or Hal, R₄ is H, CH₃, CH₂CH₃, OCH₃ or Hal, and Hal is halogen, and their non-toxic acid addition salts exhibit valuable pharmacological activity and are useful especially as selective α_2 -receptor antagonists. Processes for the preparation of these compounds and pharmaceutical compositions containing them are described.

EP 0 183 492 A1

SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE

The present invention relates to 4(5)-substituted imidazole derivatives and their non-toxic salts, and their preparation and use.

- 5 The imidazole derivatives of this invention are new potent and selective α_2 -receptor antagonists of the formula:



15

wherein X is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{O}-$, R₁ is H, alkyl of 1 to 4 carbon atoms, alkenyl of 2 to 4 carbon atoms, OCH_3 or OCH_2CH_3 , R₂ is H, CH_3 , CH_2CH_3 , OCH_3 or OH, R₃ is H, CH_3 , CH_2CH_3 , OCH_3 or Hal, R₄ is H, CH_3 , CH_2CH_3 , OCH_3 or Hal, and Hal is halogen, and their non-toxic
20 pharmaceutically acceptable acid addition salts.


The compounds of the formula (I) form acid addition salts with both organic and inorganic acids. They can thus form any pharmaceutically usable acid addition salts, as, for instance, chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, citrates, benzoates, salicylates, ascorbates and the like.

The invention includes within its scope pharmaceutical compositions comprising at least one of the compounds of formula (1) or a non-toxic, pharmaceutically acceptable salt thereof, and a compatible pharmaceutically acceptable carrier therefor.

5 Adrenergic receptors are physiologically active binding sites which are specific to noradrenaline and adrenaline and located on the surface of the cell membrane. The adrenoceptors of the sympathetic nervous system have been classified into two different subtypes, namely alpha- (α) and beta-(β) receptors which can both be further 10 divided into two subgroups, i.e. α_1 and α_2 as well as β_1 and β_2 . Of these receptor types, β_1 , β_2 and α_1 are mainly located postsynaptically on the surface of, e.g., smooth muscles and thus mediate, e.g., smooth muscle contraction or relaxation; whereas α_2 receptors are mainly located presynaptically on the terminals of noradrenergic nerves. If α_2 receptors 15 are stimulated by noradrenaline under physiological conditions, noradrenaline release is blocked, i.e. there is a negative feed-back phenomenon.

As well as by noradrenaline itself, this negative feed-back phenomenon may be induced by certain synthetic α_2 -agonists like 20 detomidine (compound A) and some of its near derivatives. The primary pharmacodynamic effects of detomidine, e.g. sedation, have also been proved to be due to its ability to stimulate α_2 -receptors (Virtanen et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry, suppl. 1983, p.308).

25 The compounds of formula (1) have valuable properties as antagonists to sedatives and analgetics used in veterinary medicine. Such veterinary medicines include, e.g., detomidine (compound A) and near derivatives thereof.



Compound A
(detomidine)

Compound A has been disclosed in e.g. Eur. Pat. Appl. 24829.

Detomidine is used in veterinary medicine, especially in the handling of horses and cattle (pharmacological restraint), whereby 5 the animal is sedated before investigation, treatment and difficult medical operations. Even a small surgical operation cannot be carried out without the use of a sedative agent.

When the treatment using detomidine has been completed, it 10 is for practical reasons desirable to interrupt and restrain its effect by a specific antagonist or antidote. The animal can then immediately be transported away from the surgery, and expensive awakening rooms are not required. The ability of the animal to control its movements and co-ordination after awakening is improved. 15 When animals are treated in cold surroundings this is absolutely necessary, because otherwise the animal will remain lying still for too long a time. When an awakening agent is used, the feeding of cattle can start more rapidly than otherwise. An interruption in feeding causes disturbances in production.

20

The use of an awakening agent in association with the use of detomidine saves time for the veterinarian as well as for the owner of the animal. The antidote makes practical the use of higher doses of detomidine, which induce a stronger analgetic effect. Thus, 25 the safety of the treatment of big animals is increased. Without any awakening agent, detomidine cannot be used in some cases, as it is often not possible to wait until the animal has recovered from the influence of detomidine.


30 A selective α_2 -antagonist may also be predicted to be of use in some diseases which are believed to be connected with deficiency of noradrenalin available in the postsynaptic adrenoceptors of the central and/or peripheral nervous system. These diseases include, e.g., endogenic depression and asthma.

Glucose and lipid metabolisms are regulated by an inhibitory mechanism involving α_2 -receptors. Thus α_2 -antagonists may be significant in the treatment of metabolic diseases like diabetes and obesity.

5


Presynaptic α_2 -receptors also take part in platelet aggregation. It has been shown that α_2 -agonists activate and antagonists inhibit human platelet aggregation (Grand & Schutter, Nature 1979, 277, 659). Thus α_2 -antagonists may be useful clinic-10 ally in pathogenic states involving increasing aggregation, e.g. migraine. The acute effects of ergotamine, a classical compound against migraine, are regarded as being due to its α_1 -agonist effect. Thus compounds with both antagonist effects of α_2 -receptors and agonist effects of postsynaptic α_1 -receptors may have great 15 advantages in the acute and preventive treatment of migraine.

The compounds of the formula (I) can be prepared by the following processes:



- 5 -

wherein each of R_5 , R_6 , R_7 and R_8 is hydrogen, hydroxy, halogen, amino, $-O-$ alkyl containing 1 to 7 carbon atoms, or





5

(wherein R_9 is an alkyl radical containing 1 to 7 carbon atoms or an aryl radical containing 6 to 10 carbon atoms); and wherein R_5 and R_7 can be combined to form a keto group, or R_6 and R_8 can be combined to form a keto group.



10

In process B, the following compounds can for example be used as starting materials:


15



25




30




- 6 -


A particularly convenient way to perform process B is the following (B1):



Another advantageous adaptation of process B is B2:





C.





wherein R_3 is a halogen atom and R_4 is H or both R_3 and R_4 are 10 halogens.


D.






E.




0183492



wherein R is a benzyl group.





In process A the halogenation step can be performed by reaction 15 with e.g. bromine in methylene chloride or diethyl ether with stirring at about 10°C.

In the second step the halogenated product and formamide are heated at 130-200°C for 3-8 hours.

20

The catalytic hydrogenation is performed in acidic water-ethanol mixture at about 70°C at normal or elevated pressure using e.g. Pd/C as catalyst.

25 In process B1 the first and second steps are performed in the same way as the corresponding steps in process A.

Process B2. The Grignard reaction is carried out in an ether, e.g. tetra-hydrofuran or diethyl ether, at room temperature.


30

The reduction step is performed with e.g. sodium borohydride in ethanol at room temperature. The reaction with formamide is carried out as in A and B1, namely by heating at 130-200°C for 3-8 hours.

5 Process C. The halogenation is carried out with e.g. bromine in acidified water at about 10°C.


The following compounds of formula I are of special value as α_2 -antagonists:

10



15 Compound I


4(5)-(2,3-dihydro-1H-inden-2-yl)-imidazole

20
20

Compound II

4(5)-(2,3-dihydrobenzofuran-2-yl)imidazole


25 Br



30 Compound III


4(5)-(5-bromo-2,3-dihydrobenzofuran-2-yl)imidazole

35




Compound IV

4(5)-(2,3-dihydro-5-methyl-1H-inden-2-yl)imidazole




Compound V

4(5)-(4-methyl-2,3-dihydro-1H-inden-2-yl)imidazole




5 Compound VI

4(5)-(2,3-dihydro-1-methyl-1H-inden-2-yl)imidazole




Compound VII

4(5)-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole




Compound VIII

4(5)-(2,3-dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole




Compound IX

15 4(5)-(5-chloro-2,3-dihydro-1H-inden-2-yl)imidazole




Compound X

4(5)-(5-bromo-2,3-dihydro-1H-inden-2-yl)imidazole




5 Compound XI

4(5)-(2,3-dihydro-1-hydroxy-1H-inden-2-yl)imidazole




Compound XII

4(5)-(2,3-dihydro-2-methyl-1H-inden-2-yl)imidazole




Compound XIII

4(5)-(4-chloro-2,3-dihydro-1H-inden-2-yl)imidazole




Compound XIV


4(5)-(4-bromo-2,3-dihydro-1H-inden-2-yl)imidazole




Compound XV

4(5)-(2,3-dihydro-2-ethyl-1H-inden-2-yl)imidazole

5 Compound XVI

4(5)-(2,3-dihydro-2,5-dimethyl-1H-inden-2-yl)imidazole

Compound XVII

4(5)-(2,3-dihydro-2-ethyl-5-methyl-1H-inden-2-yl)imidazole

Compound XVIII

4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole

The pharmacological activity of the compounds of the present invention was determined as follows:

1. α_2 -antagonism in vitro

α_2 -antagonism was determined by means of isolated, electrically stimulated mouse vas deferens preparation (Marshall et al., Br. J. Pharmac. 62, 147, 151, 1978). In this model, α_2 -agonist (detomidine) blocks electrically stimulated muscular contractions and the effect of the α_2 -antagonist is seen by administering it prior to the agonist and by determining its pA_2 value. Known α_2 -antagonists like yohimbine and rauwolscine were used as reference substances.

To obtain information also on the selectivity of the antagonist between α_1 - and α_2 -receptors, its ability to inhibit or stimulate α_1 -receptors was determined by means of isolated anococcygeus muscle (rat). The reference substances were now phenylephrine, a known α_1 -agonist, and prazosin, a known α_1 -antagonist. To determine α -antagonism, muscular contraction was induced by phenylephrine and the pA_2 value of the studied compound was determined as above. α_1 -agonist effect is presented as the pD_2 value (negative logarithm of the molar concentration of the compound producing 50 per cent of maximal contraction). Examples of the results are given in Table 1.

TABLE 1. α_2 -antagonism α_1 -antagonism α_1 -agonism
 (pA₂ vs detomidine) (pA₂ vs phenyl- (pD₂)
 mouse vas deferens ephrine) rat
 rat anococcygeus anococcygeus

	Compound I	8.8	-	6.5
	Compound II	7.5	-	5.5
	Compound III	6.2	-	4.5
	Compound IV	7.7	-	6.5
10	Compound VI	8.7	-	6.5
	Compound VII	7.6	-	6.0
	Compound VIII	7.6	5.9	-
	Compound XII	8.1	-	5.5
	Compound XV	8.3	-	-
15	Compound XVII	6.6	-	-
	Compound XVIII	7.7	-	6.0
	Yohimbine	8.1	6.6	-
	Rauwolscine	8.1	6.3	-
	Prazosin	< 5	9.0	-
20	Phenylephrine	-	-	6.5

2. α_2 -antagonism in vivo

The central α_2 -blocking effect of the studied substances under in vivo conditions was studied using two methods. First, it is known that in the rat α_2 -agonists induce dilatation of the pupil (mydriasis) which effect is transmitted via α_2 -receptors of the central nervous system. In anaesthetized rat, a standard dose of detomidine was administered intravenously. Thereafter increasing doses of the studied antagonist were injected intravenously and the reversal of detomidine-induced mydriasis was followed. The ED₅₀ value of the antagonist, i.e. the dose producing a 50 per cent reversal, was determined. Examples of the results of this test are presented in Table 2.

Table 2.

	Compound	ED ₅₀ (μ g/kg iv)
5	I	3
	II	70
	III	320
	IV	20
	VI	100
	VII	100
10	VIII	100
	XII	3
	XV	6
	Yohimbine	200
	Phentolamine	1000
15	Prazosin	>1000

α_2 -antagonism in the central nervous system was secondly studied by following the ability of the antagonist to inhibit 20 detomidine induced sedation in the mouse. This was done by measuring the increase of barbiturate sleeping time induced by detomidine. This effect of detomidine is known to be induced through α_2 -receptor activation. The antagonist can be studied by administering it prior to detomidine. The results of the 25 selected compounds are shown in Table 3.

Table 3. Effect of different antagonists (+ per cent of controls) on detomidine (150 μ g/kg ip) induced potentiation of the barbiturate sleeping time in mice

Dose mg/kg	Compound I	Compound II	yohimbine	prazosin
35 0.3	0.1 -20	-5	0	0
	0.3 -60	-30	-18	0
	1 -100	-60	-64	0
	3 not measured	-70	-70	+16
	10 not measured	-85	-100	+18

In the examples below, where ^1H and ^{13}C NMR spectrum shifts are presented, the NMR spectra were determined with a Bruker WB 80 DS apparatus using an internal tetramethylsilane standard, from which the presented chemical shifts (δ , ppm) are tabulated. The letters s, d, t and m are used to indicate a singlet, doublet, triplet or multiplet, respectively. In the same connection, the number of hydrogen atoms is also stated. The compounds which are indicated as bases are tested in deuterium methanol, deuterium acetone or deuterium chloroform, while the values for compounds which are indicated as hydrochlorides were determined in deuterium oxide or deuterium methanol. The mass spectra were determined with a Kratos MS 80 Autoconsole apparatus.


Example 1

4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

The 1-(2,3-dihydro-1H-inden-2-yl)ethanone used as the starting material can be obtained according to the publication (Carlson, G. L. B., Quina, F. H., Zarnegar, B. M. and Whitten, D. G., J. Am. Chem. Soc. 97 (1975) 347).

a) 2-Bromo-1-(2,3-dihydro-1H-inden-2-yl)ethanone

Bromine (6.8 g) is slowly added to a stirred solution of 1-(2,3-dihydro-1H-inden-2-yl)ethanone (6.8 g) in 200 ml of dry ether, while keeping the temperature at + 10°C. The rate of the addition of bromine is controlled so that the colour due to one added portion of bromine has been discharged before another portion is added. When the addition is complete, the ethereal solution is washed four times with 3 M sodium carbonate solution, and is then washed three times with water. The ethereal solution is dried with anhydrous magnesium sulphate. After removal of the solvent the solid 2-bromo-1-(2,3-dihydro-1H-inden-2-yl)ethanone is obtained.

MS (m/z, % the relative intensity): 240 and 238 (8 and 12, M^{+}), 159 (47, $\text{M}-\text{Br}$), 145 (31, $\text{M}-\text{CH}_2\text{Br}$), 117 (73, $\text{M}-\text{COCH}_2\text{Br}$), 116 (78), 115 (100, 

b) 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

A mixture of 2-bromo-1-(2,3-dihydro-1H-inden-2-yl)ethanone (9.4 g) and formamide (140 ml) is heated at 170-180°C for 4 hours. Then the reaction mixture is allowed to cool to ambient temperature and poured into ice-cold, dilute hydrochloric acid solution. The mixture is washed twice with toluene. Then the aqueous layer is made alkaline with ammonia and extracted several times with ethyl acetate. The combined organic layers are dried over anhydrous magnesium sulfate and evaporated to dryness under reduced pressure. The oily residue, which contains the crude product of 4(5)-(2,3-dihydro-1H-inden-2-yl)imidazole is purified by flash chromatography (solvent system: methylene chloride - methanol 9.5:0.5). The 4(5)-(2,3-dihydro-1H-inden-2-yl)imidazole thus obtained is converted to its hydrochloride salt. The base is dissolved in ethyl acetate. Dry hydrogen chloride in ethyl acetate is added. The hydrochloride is precipitated with dry ether.

20 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole hydrochloride:

MS: 184 (100 M⁺), 183 (71, M-H), 169 (89, M-CH₃), 156 (32), 150 (10), 147 (12), 142 (17), 141 (10), 139 (18), 129 (20), 128 (24), 127 (15), 119 (12), 116 (23), 115 (36), 111 (10), 91 (25), 25 77 (8), 69 (20)

¹H NMR (80 MHz, MeOH-d₄): 2.93-3.83 (5H, m, H₂¹, H² and H₂³), 7.08-7.27 (4H, m, aromatic), 7.35 (1H, dd, im-5(4)), 8.83 (1H, d, ⁴J = 1.37 Hz, im-2)

30

¹³C NMR (20 MHz, MeOH-d₄): 36.80 (OFR d, C₂), 39.71 (2t, C₁ and C₃), 115.96 (d, im-5(4)), 125.32 (2d, aromatic), 127.86 (2d, aromatic), 134.85 (d, im-2), 138.76 (s, im-4(5)), 142.42 (2s, C₈ and C₉)

Example 2

4(5)-(2,3-Dihydrobenzofuran-2-yl)imidazole

a) 1-(Benzofuran-2-yl)-2-bromoethanone

5 Benzofuran-2-yl methyl ketone (20 g) is dissolved in 100 ml of methylene chloride and 3.2 ml of bromine in methylene chloride is added at 5-10°C. Then the reaction mixture is stirred at + 15°C for 2 hours. Then it is washed with water, with diluted sodium bicarbonate solution and again with water. The organic phase is 10 dried and evaporated to dryness to give crude 1-(benzofuran-2-yl)-2-bromoethanone.

b) 4(5)-(Benzofuran-2-yl)imidazole

15 The crude product from step a) (12.1 g) and formamide (60 ml) are combined and heated at 170°C for 5 hours. The reaction mixture is poured in water and concentrated hydrochloric acid added to make the mixture acidic. It is then washed with methylene chloride and the aqueous phase is made alkaline with 20 sodium hydroxide. The product is extracted into methylene chloride which thereafter is washed with water, dried with sodium sulfate and evaporated to dryness. The residue consisting of crude product is converted to its hydrochloride salt in ethyl acetate. M.p. 229-235°C.

25

^1H NMR (80 MHz, D_2O): 4.96 (2H, s), 6.77 (1H, s), 7.16-7.49 (6H, m), 8.46 (1H, s)

c) 4(5)-(2,3-Dihydrobenzofuran-2-yl)imidazole

30

The product from step b) (5 g) is dissolved in water (60 ml) and ethanol (30 ml) and concentrated hydrochloric acid (9 ml) is added. Then the reaction mixture is hydrogenated at 60°C with 10 % palladium on carbon as catalyst until no more hydrogen is consumed.

Then the catalyst is filtered and ethanol is distilled off. The aqueous solution is washed with methylene chloride and made alkaline with sodium hydroxide. The product is extracted into toluene. The toluene is washed with water and evaporated. The residue is crystallized from toluene-isopropanol and is then converted to its hydrochloride salt in isopropanol-ether. The yield is 1.3 g, m.p. 177-178°C.

MS: 186 (46 %), 185 (13 %), 170 (15 %), 169 (100 %), 159 (5 %),
10 158 (8 %), 157 (7 %), 146 (16 %), 142 (43 %), 131 (11 %), 130
(20 %), 103 (10 %)

Example 3

15 4(5)-(5-Bromo-2,3-dihydrobenzofuran-2-yl)imidazole

4(5)-(2,3-dihydrobenzofuran-2-yl)imidazole (0.6 g) and water (8 ml) are combined. Concentrated hydrochloric acid is added until the solution is acidic. Bromine (0.52 g) is added dropwise at about 10°C and the mixture is stirred at this temperature for another half an hour. The precipitated product is filtered off and washed with water. The crude product is dissolved in warm water and the undissolved material filtered off. The filtrate is made alkaline with sodium hydroxide and the precipitate is filtered off. The product is converted to its hydrochloride salt in isopropanol-ether. The yield of 4-(5-bromo-2,3-dihydrobenzofuran-2-yl)imidazole hydrochloride is 0.4 g, m.p. 202-204°C. M.p. of the base is 187-188°C.

30 Example 4

cis- 4(5)-(2,3-Dihydro-1-methyl-1H-inden-2-yl)imidazole

The cis-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid used as the starting material can be obtained according to the literature (for example Shadbolt, R. S., J. Chem. Soc. (C), (1970) 920).

a) cis-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid chloride

cis-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid (52.6 g) is converted to its acid chloride by treatment with thionyl chloride (130 ml). Excess thionyl chloride is distilled off and the acid chloride is distilled, b.p. 86-89°C/0.45 mmHg. The yield is 47.9 g, 83 %.

b) cis-1-(2,3-Dihydro-1-methyl-1H-inden-2-yl)ethanone

10

cis-1-(2,3-Dihydro-1-methyl-1H-inden-2-yl)ethanone is prepared by the treatment of cis-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid chloride with ethoxymagnesiummalonic acid ethyl ester in dry ether and thereafter by the treatment of sulfuric acid according to the publication (Reynolds, G. A. and Hauser, C. B., Org. Synth. 30 (1957) 70). The yield is 92 %.

cis-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone:

20 MS : 174 (31, M⁺⁺), 159 (71, M-CH₃), 131 (38, M-COCH₃), 130 (100), 129 (27), 128 (21), 116 (24), 115 (54), 91 (33), 43 (16, COCH₃)

1^H NMR (80 MHz, CDCl₃): 1.36 (3H, d, J 6.67 Hz, >CHCH₃), 2.24 (3H, s, COCH₃), 2.79-3.64 (4H, m, H¹, H² and H₂³ of the indane ring), 7.17 (4H, s, aromatic)


1³C NMR (20 MHz, CDCl₃): 19.60, 28.99, 34.80, 41.58, 61.05, 123.17, 124.13, 126.65, 126.71, 140.48, 146.38, 208.99

c) 2-Bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)-ethanone

Bromine in methylene chloride is slowly added to a stirred
 5 solution of cis-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone
 (34.8 g) in methylene chloride (835 ml), while keeping the
 temperature at + 10°C. The reaction is followed by GLC. The
 first products are the isomers of 1-(2-bromo-2,3-dihydro-1-
 methyl-1H-inden-2-yl)ethanone and cis-2-bromo-1-(2,3-dihydro-1-
 10 methyl-1H-inden-2-yl)ethanone. When the added amount of bromine
 is about 0.3 mol, only the final product, 2-bromo-1-(2-bromo-
 2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone is visible in the
 chromatogram and the mono bromo products cannot be seen in the
 chromatogram any more. The methylene chloride solution is washed
 15 with water, then several times with the diluted NaHCO₃ solution
 and finally with water. The solvent is dried with Na₂SO₄ and
 evaporated to dryness.

2-bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone:

20

MS of the isomer a : 334, 332, 330 (0.5, 1, 0.5, M⁺), 253 and
 251 (65 and 68, M-Br), 211 and 209 (1 and 1, M-COCH₂Br), 172
 (11), 157 (28), 148 (26), 131 (15), 130 (80), 129 (93), 128
 (79), 127 (30), 123 (22), 121 (23), 115 (100, , 102
 25 (10), 95 (14), 93 (14), 77 (11).

MS of the isomer b : M⁺ invisible, 253 (65), 251 (69), 209 (1),
 211 (1), 172 (17), 157 (38), 143 (28), 131 (14), 130 (69), 129
 (100), 128 (85), 127 (35), 123 (18), 121 (18), 115 (95), 102
 30 (11), 95 (13), 93 (14), 77 (12).

cis-2-bromo-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone:

If the products are isolated, when 0.2 mol of bromine (instead
 35 of 0.3 mol) has been added, the following mixture of

products is obtained: 1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone, cis-2-bromo-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone and 2-bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone. Also a little amount of the starting compound can be seen in the chromatogram.

MS : M^{+} invisible, 173 (100, M-Br), 155 (12), 145 (26), 143 (10), 131 (31, M-GOCH₂Br), 130 (16), 129 (29), 128 (26), 127 (14), 116 (29), 115 (59), 91 (28).

10

d) 4(5)-(1-Methyl-inden-2-yl)imidazole

2-Bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone (34.0g) and formamide (520 ml) are combined and the mixture is heated with stirring at 170°C for about 3 hours. The reaction mixture is cooled, then poured into water, made acidic with hydrochloric acid and washed with methylene chloride. The aqueous layer is then made alkaline with sodium hydroxide and the mixture is extracted with ethyl acetate. The organic extracts are washed with water and dried and evaporated to dryness. The residue, which consists of the crude product, is converted to the hydrochloride salt in ethyl acetate. After the recrystallization of the hydrochloride from isopropanol-ethanol the yield of the product is 11.4 g, 48 % (m.p. 265 - 268°C).

25

The hydrochloride salt of 4(5)-(1-methyl-inden-2-yl)imidazole:

MS : 196 (100, M^{+}), 195 (44, M-H), 181 (30, M-CH₃), 168 (10), 167 (10), 141 (12), 139 (9), 127 (12), 115 (10), 98 (8), 97 (9).

30

¹H NMR (80 MHz, MeOH-d₄): δ 2.34 (3H, t, ⁵J 2.22 Hz, CH₃), 3.75 (2H, q, ⁵J 2.22 Hz, >CH₂), 7.16 - 7.55 (4H, m, aromatic), 7.71 (1H, d, im-5(4)), 8.97 (1H, d, ⁴J 1.37 Hz, im-2).

^{13}C NMR (20 MHz, MeOH-d₄): δ 12.10 (OFR q), 40.16 (t), 116.81 (d), 120.75 (d), 124.56 (d), 126.04 (s), 127.19 (d), 127.74 (d), 131.49 (s), 134.79 (d), 141.06 (s), 143.30 (s), 146.63 (s).

5 e) 4(5)-(2,3-Dihydro-1-methyl-1H-inden-2-yl)imidazole

The crude product of 4(5)-(1-methyl-inden-2-yl)imidazole (3.3 g) is dissolved in water (40 ml)-ethanol (20 ml)-concentrated 10 hydrochloric acid (6 ml) solution. Then 0.33 g of 10 % Pd/C is added and the mixture is stirred vigorously under a hydrogen atmosphere at about 60°C until no more hydrogen is consumed. The reaction mixture is then filtered and the filtrate is evaporated to a smaller volume. The acidic solution is washed with 15 methylene chloride. The aqueous phase is then made alkaline and extracted with methylene chloride. The organic extracts are dried and evaporated to dryness. The crude cis-4(5)-(2,3-dihydro-1-methyl-1H-inden-2-yl)imidazole is purified by converting it into the hydrochloride salt in acetone-ethyl acetate. The melting point of the hydrochloride is 192 - 194 °C.

The hydrochloride salt of cis-4(5)-(2,3-dihydro-1-methyl-1H-inden-2-yl)imidazole:

25MS : 198 (100, M⁺), 197 (27, M-H), 183 (78, M-CH₃), 170 (14), 169 (43), 156 (17), 154 (18), 142 (11), 130 (36), 129 (24), 128 (27), 127 (15), 117 (14), 116 (12), 115 (44), 91 (25), 82 (17), 81 (30), 77 (11).

30

^1H NMR (80 MHz, MeOH-d₄): δ 0.94 (3H, d, ^3J 7.01 Hz, CH₃), 3.23 - 4.03 (4H, m, H¹, H² and H₂³), 7.19 - 7.25 (5H, m, aromatic and im - 5(4)), 8.85 (1H, d, ^4J 1.37 Hz, im-2).

35 ^{13}C NMR (20 MHz, DMSO-d₆): δ 16.34 (OFR q), 34.41 (t), 39.23 (d), 41.95 (d), 115.73 (d), 123.66 (d), 124.08 (d), 126.50 (2d), 133.28 (d), 133.77 (s), 140.49 (s), 147.00 (s).

Example 5

cis-4(5)-(2,3-Dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole5 a) α -Acetyl-4-methylbenzenepropanoic acid ethyl ester

The starting material, α -acetyl-4-methylbenzenepropanoic acid ethyl ester can be prepared for example according to the publication by L. Borowiecki and A. Kazubski (Pol. J. Chem. 52 10 (1978) 1447). Yield 60 %, b.p. 120 - 150°C/0.15 mmHg.

 α -Acetyl-4-methylbenzenepropanoic acid ethyl ester:

¹H NMR (80 MHz, CDCl₃): δ 1.20 (3H, t, J 7.18 Hz, CH₂CH₃), 2.17 (3H, s, CH₃CO or ArCH₃), 2.29 (3H, s, ArCH₃ or CH₃CO), 3.11 (2H, distorted d, J_{ab} 7.58 Hz, >CHCH₂-), 3.74 (1H, distorted t, J_{ab} 7.58 Hz, >CHCH₂-), 4.14 (2H, q, J 7.18 Hz, CH₂CH₃), 7.06 (4H, s, aromatic).

¹³C NMR (20 MHz, CDCl₃): δ 13.91, 20.88, 29.35, 33.56, 61.23, 61.35, 128.49 (2), 129.10 (2), 134.97, 136.00, 169.00, 202.15.

b) 1,6-Dimethyl-indene-2-carboxylic acid

25 The 1,6-dimethyl-indene-2-carboxylic acid can be prepared by the treatment of α -acetyl-4-methylbenzenepropanoic acid ethyl ester with sulfuric acid (Shadbolt, R.S., J. Chem. Soc. (C), (1970) 920). Recrystallization from ethanol, m.p. 174 - 182 °C. Yield 59 %.

30

1,6-dimethyl-indene-2-carboxylic acid:

¹H NMR (80 MHz, DMSO-d₆): δ 2.38 (3H, s, ArCH₃), 2.46 (3H, t, ⁵J 2.39 Hz, =CH₃), 3.53 (2H, q, ⁵J 2.39 Hz, CH₂), 6.68 (1H, broad s, COOH), 7.11 - 7.44 (3H, m, aromatic).

^{13}C NMR (20 MHz, DMSO-d₆): δ 11.95 (OFR q), 20.97 (q), 38.14 (t), 121.33 (d), 123.51 (d), 128.20 (d), 130.59 (s), 135.59 (s), 140.07 (s), 145.06 (s), 149.60 (s), 166.49 (s).

5 c) 1,6-Dimethyl-indene-2-carboxylic acid chloride

1,6-Dimethyl-indene-2-carboxylic acid (37.3 g) is converted to its acid chloride by treatment with thionyl chloride (580 ml). Excess thionyl chloride is distilled off. Yield 40.5 g, 99 %.

10

d) 1-(1,6-Dimethyl-inden-2-yl)ethanone

1-(1,6-Dimethyl-inden-2-yl)ethanone is prepared by the same procedure as cis-1-(2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone in Example 4b. A mixture of dry ether and tetrahydrofuran is used as solvent. Yield 84 %.

1-(1,6-Dimethyl-inden-2-yl)ethanone:

20 MS: 186 (68, M⁺ *), 171 (35, M-CH₃), 144 (39), 143 (100, M-COCH₃), 142 (13), 141 (32), 129 (17), 128 (71), 127 (16), 115 (26), 43 (77, COCH₃).

^1H NMR (80 MHz, CDCl₃): δ 2.41 (3H, s, ArCH₃ or COCH₃), 2.42 (3H, s, COCH₃ or ArCH₃), 2.51 (3H, t, ^5J 2.39 Hz, = C¹-CH₃), 3.61 (2H, q, ^5J 2.39 Hz, CH₂), 7.11 - 7.41 (3H, m, aromatic).

^{13}C NMR (20 MHz, CDCl₃): δ 12.85 (OFR q), 21.39 (q), 30.02 (q), 38.80 (t), 122.02 (d), 123.62 (d), 129.01 (d), 136.36 (s), 137.82 (s), 140.24 (s), 145.60 (s), 149.87 (s), 196.49 (s).

e) 2-Bromo-1-(1,6-dimethyl-1H-inden-2-yl)ethanone

Bromine (2.80 g) is added to 1-(1,6-dimethyl-inden-2-yl)ethanone (3.00 g) in dry ether (30 ml), while keeping the temperature at 5 +10°C. The mixture is extracted with water, several times with the diluted NaHCO₃ solution, again with water, dried and evaporated under reduced pressure to afford the product (2.54 g, 59 %).

10 2-bromo-1-(1,6-dimethyl-1H-inden-2-yl) ethanone:

MS: 266 and 264 (13 and 13, M⁺⁺), 185 (4, M-Br), 171 (100, M-CH₂Br), 157 (13), 143 (49, M-COCH₂Br), 142 (18), 141 (32), 128 (27), 115 (18).

15

f) 4(5)-(1,6-Dimethyl-1H-inden-2-yl)imidazole

4(5)-(1,6-Dimethyl-1H-inden-2-yl)imidazole is prepared by the reaction of 2-bromo-1-(1,6-dimethyl-1H-inden-2-yl)ethanone (14.3 20 g) with formamide (130 ml) as described earlier in Example 4d. The crude base is purified by flash chromatography (solvent system: methylene chloride - methanol 9.5:0.5). The 4(5)-(1,6-dimethyl-1H-inden-2-yl)imidazole thus obtained is converted to its hydrochloride salt. The base is dissolved in ethyl acetate. 25 After dry hydrogen chloride in ethyl acetate is added the hydrochloride salt precipitates.

The base of 4(5)-(1,6-dimethyl-1H-inden-2-yl)imidazole:

30 ¹H NMR (80 MHz, MeOH-d₄): δ 2.28 (3H, t, ⁵J 2.05 Hz, =C¹-CH₃), 2.38 (3H, s, ArCH₃), 3.64 (2H, q, ⁵J 2.05 Hz, CH₂), 6.91-7.33 (4H, m, aromatic and im-5(4)), 7.73 (1H, d, ⁴J 0.86 Hz, im-2).

The hydrochloride salt of 4(5)-(1,6-dimethyl-inden-2-yl)-imidazole:

¹H NMR (80 MHz, MeOH-d₄): δ 2.33 (3H, t, ⁵J 2.22 Hz, =C¹-CH₃),
 5 2.41 (3H, s, ArCH₃), 3.71 (2H, q, ⁵J 2.22 Hz, CH₂), 7.05-7.43
 (3H, m, aromatic), 7.70 (1H, d, im-5(4)), 8.96 (1H, d, ⁴J 1.37
 Hz, im-2).

g) cis-4(5)-(2,3-Dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole

10

The hydrochloride salt of 4(5)-(1,6-dimethyl-inden-2-yl)-imidazole (0.55 g) is dissolved in water (6 ml)-ethanol (3 ml)-concentrated hydrochloric acid (4 ml) solution. Hydrogenation is performed as it is described in Example 4e. The cis-4(5)-(2,3-dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole is converted into the hydrochloride salt in ethylacetate. The melting point of the hydrochloride salt is 192-196 °C.

The hydrochloride salt of cis-4(5)-(2,3-dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole:

MS: 212 (100, M⁺•), 211 (25, M-H), 197 (73, M-CH₃), 183 (41),
 170 (14), 168 (14), 144 (25), 141 (10), 131 (22), 129 (19), 126
 (20), 115 (14), 98 (12), 91 (15).

25

¹H NMR (80 MHz, MeOH-d₄): δ 0.93 (3H, d, J 7.01 Hz, >CHCH₃),
 2.31 (3H, s, ArCH₃), 3.16-4.00 (4H, m, H¹, H² and H³), 6.96-
 7.12 (3H, m, aromatic), 7.24 (1H, broad s, im-5(4)), 8.85 (1H,
 d, ⁴J 1.37 Hz, im-2).

30

¹³C NMR (20 MHz, MeOH-d₄): δ 16.49 (OFR q), 21.39 (q), 36.17
 (t), 41.83 (d), 43.98 (d), 117.17 (d), 125.14 (d), 125.38 (d),
 128.74 (d), 134.63 (d), 136.55 (s), 137.82 (s), 138.70 (s),
 148.14 (s).

Example 6

cis-4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole

Method A:

5

a) α -Acetyl-2-methylbenzenepropanoic acid ethyl ester

The starting material, α -acetyl-2-methylbenzenepropanoic acid ethyl ester can be prepared for example according to the 10 publication by L. Borowiecki and A. Kazubski (Pol. J. Chem. 52 (1978) 1447). Yield 64 %, b.p. 142 - 152 °C/1.5 mmHg.

 α -acetyl-2-methylbenzenepropanoic acid ethyl ester:

15 ^1H NMR (80 MHz, CDCl_3): δ 1.19 (3H, t, J 7.18 Hz, CH_2CH_3), 2.18 (3H, s, CH_3CO or ArCH_3), 2.32 (3H, s, ArCH_3 or CH_3CO), 3.17 (2H, distorted d, J_{ab} 7.58 Hz, CHCH_2-), 3.76 (1H, distorted t, J_{ab} 7.58 Hz, CHCH_2-), 4.14 (2H, q, J 7.18 Hz, CH_2CH_3), 7.10 (4H, s, aromatic).

20

b) 1,4-Dimethyl-indene-2-carboxylic acid

The 1,4-dimethyl-indene-2-carboxylic acid can be prepared by the treatment of α -acetyl-2-methylbenzenepropanoic acid ethyl ester 25 with sulfuric acid (Shadbolt, R.S., J. Chem. Soc. (C), (1970) 920). Recrystallization from ethanol, m.p. 190 - 193 °C. Yield 61%.

1,4-dimethyl-indene-2-carboxylic acid:

30

^1H NMR (80 MHz, DMSO-d_6): δ 2.33 (3H, s, ArCH_3), 2.46 (3H, t, J 2.39 Hz = CH_3), 3.48 (2H, q, J 2.39 Hz, CH_2), 7.09 - 7.42 (4H, m, aromatic and -COOH).

30

^{13}C NMR (20 MHz, DMSO-d₆): δ 12.04 (OFR q), 17.86 (q), 37.44 (t), 118.51 (d), 126.68 (d), 128.26 (d), 130.11 (s), 132.71 (s), 141.67 (s), 144.42 (s), 149.81 (s), 166.43 (s).

5 c) 1,4-Dimethyl-indene-2-carboxylic acid chloride

1,4-Dimethyl-indene-2-carboxylic acid is converted to its acid chloride by treatment with thionyl chloride. Yield 100 %.

10 d) 1-(1,4-Dimethyl-inden-2-yl)ethanone

1-(1,4-Dimethyl-inden-2-yl)ethanone is prepared by the same procedure as 1-(1,6-dimethyl-inden-2-yl)ethanone in Example 5d. Yield 75 %.

15

1-(1,4-Dimethyl-inden-2-yl)ethanone:

MS: 186 (60, M⁺), 171 (29, M-CH₃), 144 (33), 143 (100, M-COCH₃), 141 (27), 129 (18), 128 (66), 127 (15), 115 (28), 43 (20, COCH₃).

^1H NMR (80 MHz, CDCl₃): δ 2.38 (3H, s, ArCH₃ or COCH₃), 2.46 (3H, s, COCH₃ or ArCH₃), 2.53 (3H, t, ⁵J 2.39 Hz, =C¹ - CH₃), 3.55 (2H, q, ⁵J 2.39 Hz, CH₂), 7.10 - 7.46 (3H, m, aromatic).

25

^{13}C NMR (20 MHz, CDCl₃): δ 13.13 (OFR q), 18.33 (q), 30.14 (q), 38.13 (t), 119.23 (d), 127.13 (d), 129.10 (d), 133.25 (s), 137.55 (s), 141.84 (s), 145.14 (s), 150.17 (s), 196.46 (s).

30 e) 2-Bromo-1-(1,4-dimethyl-inden-2-yl)ethanone

2-Bromo-1-(1,4-dimethyl-inden-2-yl)ethanone is prepared by the same procedure as 2-bromo-1-(1,6-dimethyl-inden-2-yl)ethanone in Example 5e. Yield 45 %.

35

2-bromo-1-(1,4-dimethyl-inden-2-yl)ethanone:

MS: 266 and 264 (14 and 15, M⁺), 185 (3, M-Br), 171 (100, M-CH₂Br), 157 (13), 143 (M-COCH₂Br), 142 (18), 141 (33), 128 (32), 115 (21).

f) 4(5)-(1,4-Dimethyl-inden-2-yl)imidazole

4(5)-(1,4-Dimethyl-inden-2-yl)imidazole is prepared by the reaction of 2-bromo-1-(1,4-dimethyl-inden-2-yl)ethanone (8.7 g) with formamide (330 ml) as described earlier in Example 4d. The product as base is extracted into methylene chloride. The yield of the base product is 3.0 g, 44 %.

g) cis-4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole
10

The crude product of 4(5)-(1,4-dimethyl-inden-2-yl)imidazole (3.0 g) is dissolved in water (35 ml) -ethanol (18 ml)-concentrated hydrochloric acid (17.4 ml) solution. Then 0.30 g of 10 % Pd/C is added and the mixture is stirred under a hydrogen atmosphere at about 60 °C until no more hydrogen is consumed. Work-up of the reaction mixture is as before in Example 4e. The crude imidazole derivative is purified by flash chromatography (solvent system: methylene chloride/methanol 9.5/0.5). The cis-4(5)-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)-20 imidazole is converted into its hydrochloride salt in isopropanol/ethyl acetate and ether is added to precipitate the salt, m.p. 135-140 °C.

The hydrochloride salt of cis-4(5)-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole:

MS: 212 (100, M^{+}), 211 (30, $M-CH_3$), 197 (80), 184 (13), 183 (34), 182 (11), 170 (13), 168 (16), 144 (35), 143 (10), 141 (11), 131 (14), 129 (15), 128 (12), 127 (10), 115 (17), 98 (16), 30 91 (15).

1H NMR (80 MHz, MeOH-d₄): δ 0.92 (3H, d, 3J 6.84 Hz, $CH_3CH<$), 2.31 (3H, s, ArCH₃), 3.14-4.01 (4H, m, H¹, H² and H₂³), 6.98-7.09 (3H, m, aromatic), 7.28 (1H, broad s, im-5(4)), 8.83 (1H, d, 4J 1.37 Hz, im-2).

¹³C NMR (20 MHz, MeOH-d₄): δ 16.79 (OFR q), 19.06 (q), 34.95 (t), 41.13 (d), 44.16 (d), 117.20 (d), 122.14 (d), 128.25 (d), 128.77 (d), 134.67 (d), 134.88 (s), 136.49 (s), 140.30 (s), 147.87 (s).

5

Method B:

a) cis-2,3-Dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid

10 1,4-Dimethyl-indene-2-carboxylic acid (35.5 g) is hydrogenated in ethanol-water (700 ml - 70 ml) over 10 % palladium on carbon at ambient temperature. After filtration ethanol is evaporated. Water is added and the precipitated cis-2,3-dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid is filtrated. Yield 33.3 g,
 15 93 % M.p. 132 - 135 °C.

cis-2,3-Dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid:

¹H NMR (80 MHz, DMSO-d₆): δ 1.08 (3H, d, J 6.78 Hz, CH₃CH₂),
 20 2.20 (3H, s, ArCH₃), 2.70 - 3.67 (4H, m, H¹, H² and H³), 6.88 - 7.08 (3H, m, aromatic), 12.15 (1H, broad s, -COOH).

¹³C NMR (20 MHz, DMSO-d₆): δ 16.95 (OFR q), 18.49 (q), 31.39 (t), 41.01 (d), 47.43 (d), 120.60 (d), 126.44 (d), 127.14 (d),
 25 133.01 (s), 139.64 (s), 146.45 (s), 174.33 (s).

b) cis-2,3-Dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid chloride

30 cis-2,3-Dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid is converted to its acid chloride by treatment with thionyl chloride. Yield 92 %.

cis-2,3-dihydro-1,4-dimethyl-1H-indene-2-carboxylic acid
 35 chloride:

¹H NMR (80 MHz, CDCl₃): δ 1.44 (3H, d, J 6.67 Hz, CH₃CH<), 2.25 (3H, s, ArCH₃), 2.84 - 4.02 (4H, m, H¹, H², H₂³), 6.92 - 7.11 (3H, m, aromatic).

5 c) cis-1-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone

1-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone is prepared by the same procedure as 1-(2,3-dihydro-1-methyl-1H-inden-2-yl)-ethanone in Example 4b. B.p. 181-182 °C/1 mmHg. Yield 55 %.

10

cis-1-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone:

¹H NMR (80 MHz, CDCl₃): δ 1.37 (3H, d, ³J 6.65 Hz, CH₃CH<), 2.26 (6H, 2s, COCH₃ and ArCH₃), 2.85-3.72 (4H, m, H¹, H² and H₂³ of the indane ring), 6.88-7.16 (3H, m, aromatic).

20

d) 2-Bromo-1-(2-bromo-2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)-ethanone

Bromination of cis-1-(2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)-ethanone (11.78 g) is performed with bromine (10.00 g)/methylene chloride (40 ml) in methylene chloride (120 ml) as in the case of 1-(1,6-dimethyl-inden-2-yl)ethanone in Example 5e. Work-up of the reaction mixture gives the light yellow oil, which contains two isomers (a and b) of 2-bromo-1-(2-bromo-2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone.

2-bromo-1-(2-bromo-2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)-ethanone:

MS of the isomer a: 348, 346, 344 (0.3, 0.5, 0.1, M⁺), 267 and 265 (77 and 77, M-Br), 186 (10), 171 (18), 157 (18), 144 (64), 143 (74), 141 (23), 129 (74), 128 (100), 127 (29), 123 (16), 121 (16), 115 (24), 43 (13).

5

MS of the isomer b: 348, 346, 344 (all invisible, M⁺⁺), 267 and 265 (71 and 78, M-Br), 186 (18), 185 (16), 171 (38), 157 (24), 144 (52), 143 (91), 141 (32), 129 (73), 128 (100), 127 (30), 123 (12), 121 (13), 115 (36), 43 (15).

10

e) 4(5)-(1,4-Dimethyl-inden-2-yl)imidazole

4(5)-(1,4-Dimethyl-inden-2-yl)imidazole is prepared from 2-bromo-1-(2-bromo-2,3-dihydro-1,4-dimethyl-1H-inden-2-yl)ethanone and formamide as described for 2-bromo-1-(2-bromo-2,3-dihydro-1-methyl-1H-inden-2-yl)ethanone in Example 4d.

f) cis-4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole
20 cis-4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole is obtained in a similar manner as in method Ag.

Example 7

25 4(5)-(2,3-Dihydro-2-methyl-1H-inden-2-yl)imidazole

a) 2,3-Dihydro-2-methyl-1H-indene-2-carboxylic acid

2,3-Dihydro-2-methyl-1H-indene-2-carboxylic acid can be prepared 30 for example by the procedure of Huebner, C.F., Donoghue, E.M., Strachan, P.L., Beak, P. and Wenkert, E. (J. Org. Chem. 27 (1962) 4465) or by the reaction of lithium N-isopropylcyclohexylamide and methyl iodide (Rathke, M.V. and Lindert, A., J. Am. Chem. Soc. 93 (1971) 2318) with 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester (prepared by the methylation of 35 2,3-dihydro-1H-indene-2-carboxylic acid in the presence of sulphuric acid) followed by hydrolysis.

2,3-dihydro-2-methyl-1H-indene-2-carboxylic acid:

¹H NMR (80 MHz, CDCl₃): δ 1.40 (3H, s, CH₃), AB quartet: δ _A 2.84, δ _B 3.52, J_{AB} 15.73 Hz (4H, 2 x CH₂), 7.17 (4H, s, aromatic), about 9.3 (1H, broad s, COOH).

¹³C NMR (20 MHz, CDCl₃): δ 24.84 (OFR q, CH₃), 43.94 (2 t, C₁ and C₃), 49.48 (s, C₂), 124.62 (2 d, aromatic), 126.62 (2 d, aromatic), 141.06 (2 s, C₈ and C₉), 183.65 (s, ∞).

10

b) 2,3-Dihydro-2-methyl-1H-indene-2-carboxylic acid chloride

A stirred mixture of 2,3-dihydro-2-methyl-1H-indene-2-carboxylic acid (6.70 g) and thionyl chloride (70 ml) is heated under reflux for 14 hr. The excess of thionyl chloride is removed and the acid chloride is distilled. Yield 5.35 g, 72 %, bp. 93-98 °C/3 mmHg.

2,3-dihydro-2-methyl-1H-indene-2-carboxylic acid chloride:

20

¹H NMR (80 MHz, CDCl₃): δ 1.51 (3H, s, CH₃), AB quartet: δ _A 2.91, δ _B 3.60, J_{AB} 15.90 Hz (4H, 2 x CH₂), 7.19 (4H, s, aromatic).

25 c) 1-(2,3-Dihydro-2-methyl-1H-inden-2-yl)ethanone

1-(2,3-Dihydro-2-methyl-1H-inden-2-yl)ethanone is prepared from 2,3-dihydro-2-methyl-1H-indene-2-carboxylic acid chloride in the same way as it is described in Example 4b. Yield 75 %.

30

1-(2,3-dihydro-2-methyl-1H-inden-2-yl)ethanone:

¹H NMR (80 MHz, CDCl₃): δ 1.32 (3H, s, \geq CCH₃), 2.20 (3H, s, COCH₃), AB quartet: δ _A 2.76, δ _B 3.39, J_{AB} 15.73 Hz (4H, 2 x CH₂), 7.17 (4H, s, aromatic).

d) 2-Bromo-1-(2,3-dihydro-2-methyl-1H-inden-2-yl)ethanone

1-(2,3-Dihydro-2-methyl-1H-inden-2-yl)ethanone (3.69 g) in methylene chloride (40 ml) is stirred and cooled at 10 °C during 5 the dropwise addition of bromine (2.82 g)/methylene chloride (10 ml). Work-up of the resultant solution gives 2-bromo-1-(2,3-di- hydro-2-methyl-1H-inden-2-yl)ethanone.

2-bromo-1-(2,3-dihydro-2-methyl-1H-inden-2-yl)ethanone:

10

MS: 254 and 252 (2 and 2, M^{+}), 239 and 237 (0.5 and 0.5, $M-CH_3$), 173 (100, $M-Br$), 159 (39, $M-CH_2Br$), 155 (13), 145 (30), 143 (10), 131 (97, $M-COCH_2Br$), 130 (30), 129 (40), 128 (34), 127 (19), 116 (29), 115 (69), 91 (50), 77 (12), 63 (10), 43 (22).

15

e) 4(5)-(2,3-Dihydro-2-methyl-1H-inden-2-yl)imidazole

4(5)-(2,3-Dihydro-2-methyl-1H-inden-2-yl)imidazole is prepared by the reaction of 2-bromo-1-(2,3-dihydro-2-methyl-1H-inden-2- yl)ethanone (2.04 g) with formamide (60 ml) as described in Example 6, method Af. Purification of the crude base via flash chromatography (methylene chloride/methanol 9.75/0.25) gave pure 4(5)-(2,3-dihydro-2-methyl-1H-inden-2-yl)imidazole. M.p. of the base 167-170 °C.

25

The base of 4(5)-(2,3-dihydro-2-methyl-1H-inden-2-yl)imidazole:

MS: 198 (44, M^{+}), 197 (13, $M-H$), 183 (100, $M-CH_3$), 129 (14), 128 (18), 115 (22), 91 (28), 77 (11).

30

1H NMR (80 MHz, $CDCl_3$): δ 1.48 (3H, s, CH_3), AB quartet: δ_A 2.98, δ_B 3.32, J_{AB} , 15.39 Hz (4H, 2 x CH_2), 6.78 (1H, s, im-5(4)), 7.16 (4H, s, aromatic), 7.54 (1H, s, im-2), 8.74 (1H, s, $>NH$).

Example 8

4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

5 a) 2-Bromo-1-(2-bromo-2,3-dihydro-1H-inden-2-yl)ethanone

The procedure of Example 1 a) is repeated, except that the amount of bromine is doubled. After removal of the solvent the crude product is used as such in step b).

10

b) 4(5)-(1H-Inden-2-yl)imidazole

The procedure of Example 1 b) is repeated. The product is recrystallized from methylene chloride.

15

c) 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

The procedure of Example 2c is repeated except that 4(5)-(1H-inden-2-yl)imidazole is used in place of 4(5)-(2,3-dihydrobenzo-20 furan-2-yl)imidazole. When the uptake of hydrogen ceases, the reaction mixture is filtered and the filtrate is made alkaline with sodium hydroxide. The separated oil is extracted into methylene chloride. The combined extracts are washed with water, dried over Na_2SO_4 , and evaporated to dryness. The crude product 25 is purified by converting it into the hydrochloride in ethyl acetate. M.p.: 184 - 191 °C.

Example 9

30 4(5)-(2,3-Dihydro-5-methyl-1H-inden-2-yl)imidazole

The procedure of Example 8 is repeated except that in place of 1-(2,3-dihydro-1H-inden-2-yl)ethanone is used 1-(2,3-dihydro-5-methyl-1H-inden-2-yl)ethanone. M.p. (HCl): 171-175 °C.

35

^1H NMR (80 MHz, CDCl_3 , as base): 2.3 (s, 3H), 2.8-3.8 (m, 5H), 6.8 (s, 1H), 7.0-7.1 (m, 3H), 7.5 (s, 1H), 9.9 (s, 1H).

Example 10

4(5)-(2,3-Dihydro-2-ethyl-5-methyl-1H-inden-2-yl)imidazole

5 The procedure of Example 1 is repeated except that in place of 1-(2,3-dihydro-1H-inden-2-yl)ethanone is used 1-(2,3-dihydro-2-ethyl-5-methyl-1H-inden-2-yl)ethanone. M.p. 54-57 °C as base.

MS: 226 (40 %), 211 (12 %), 197 (100 %), 182 (7 %), 128 (12 %),
10 98 (17 %), 84 (15 %).

Example 11

4(5)-(2,3-Dihydro-2-ethyl-1H-inden-2-yl)imidazole

15

The compound is prepared according to the procedure of Example 7 using 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester and ethyl bromide as starting materials. M.p. (HCl): 211-215 °C.

20 ^1H NMR (80 MHz, CDCl_3 , as base): 0.78 (t, 3H), 1.88 (q, 2H), 3.17 (q, 4H), 6.75 (s, 1H), 7.13 (s, 4H), 7.53 (s, 1H), 10.01 (s, 1H).

Example 12

25

4(5)-(2,3-Dihydro-2,5-dimethyl-1H-inden-2-yl)imidazole

The procedure of Example 1 is repeated except that in place of 1-(2,3-dihydro-1H-inden-2-yl)ethanone is used 1-(2,3-dihydro-30 2,5-dimethyl-1H-inden-2-yl)ethanone.

M.p.: 148-151 °C as base.

^1H NMR (80 MHz, CDCl_3 , as hydrochloride): 1.51 (s, 3H), 2.27 (s, 3H), AB quartet δ_A 3.04, δ_B 3.24 J_{AB} 15.45 Hz (4H, 2 x 35 CH_2), 6.87-6.99 (m, 4H), 9.04 (s, 1H), 14 (broad band, 2H).

Example 13

4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

a) 2,3-Dihydro-1H-inden-2-yl glyoxal diethyl acetal

5 0.73 g of magnesium turnings are covered with 90 ml of dry diethylether. To that mixture is then added 6 g of 2-bromoindane in 20 ml of dry diethylether at such a rate that a gentle boiling is maintained. When the magnesium turnings have reacted the solution containing the Grignard reagent is cooled to room 10 temperature. The reaction mixture is then added dropwise, over a period of 3 hours, to a cooled (0 - 5 °C) solution of diethoxyacetic acid piperidinyl amide (6.4 g) in 20 ml of dry diethylether. After the addition is complete, the reaction mixture is stirred for two hours at about 5 °C. The mixture is then poured 15 into a cold 2 % sulfuric acid solution (50 ml). The solution is extracted with ether and the combined ether extracts are washed with water and evaporated to dryness to give a residue of crude product, which is used without purification in step b).

20 b) 1,1-Diethoxy-2-hydroxy-2-(2,3-dihydro-1H-inden-2-yl)ethane

4 g of crude 2,3-dihydro-1H-inden-2-yl glyoxal diethyl acetal is dissolved in 20 ml of ethanol and 3.8 g of sodium borohydride is added in small portions at a temperature below 30 °C. After the 25 addition is complete, the mixture is stirred overnight at room temperature. About 15 ml of ethanol is distilled off and 30 ml of water is added. The solution is extracted with methylene chloride. The combined methyle chloride extracts are washed with water, dried with sodium sulfate, and evaporated to dryness. The 30 yield is about 4 g of oil, which is used directly in step c).

c) 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole

4 g of the oil from the preceding step and 15 ml of formamide are combined and stirred at 150 °C while passing ammonia gas into the solution for 6 hours. The mixture is cooled to room temperature and 40 ml of water is added. Concentrated hydrochloric acid is added with cooling until the pH is 3-4.

The solution is washed with toluene, cooled and the pH is adjusted to 10 - 12 with 20 % sodium hydroxide solution. The mixture is extracted with methylene chloride and the combined 10 methylene chloride extracts are extracted with 10 % acetic acid solution. The combined acetic acid extracts are made alkaline (pH 10 - 12) with 20 % sodium hydroxide solution. The product is extracted into chloroform, and the combined chloroform extracts washed with water and dried with sodium sulfate. The solution is 15 evaporated to dryness to give the product as base.

The hydrochloride is prepared by dissolving the base in ethyl acetate and adding HCl-ethyl acetate until pH is about 4. The mixture is cooled and filtered and the filter cake washed with a 20 small amount of ethyl acetate. M.p. 185 - 193 °C.

Example 14

4(5)-(1,2,3,4-Tetrahydronaphth-2-yl)imidazole

25

The starting material, 1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone can be prepared from 1,2,3,4-tetrahydro-2-naphthoic acid chloride for example by the procedure of Newman, M.S. and Mangham, J.R. (J. Am. Chem. Soc. 71 (1949) 3342) or as described in this 30 patent for many acid chlorides to afford the acetyl derivatives.

- a) The mixture of 2-bromo-1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone and 2-bromo-1-(2-bromo-1,2,3,4-tetrahydronaphth-2-yl)ethanone

Bromination of 1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone (3.00 g) in methylene chloride with bromine (2.75 g)/methylene chloride (10 ml) by the normal procedure described for example in Example 5 affords the mixture of 2-bromo-1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone and 2-bromo-1-(2-bromo-1,2,3,4-tetrahydronaphth-2-yl)ethanone.

2-bromo-1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone:

10 MS: 254 and 252 (14 and 14, M^{++}), 173 (54, $M\text{-Br}$), 159 (21, $M\text{-CH}_2\text{Br}$), 150 (11), 145 (25), 131 (46, $M\text{-COCH}_2\text{Br}$), 130 (23), 129 (100), 128 (27), 127 (12), 116 (12), 115 (26), 91 (16).

2-bromo-1-(2-bromo-1,2,3,4-tetrahydronaphth-2-yl)ethanone:

15 MS: 334, 332 and 330 (invisible, M^{++}), 253 and 251 (96 and 100, $M\text{-Br}$), 172 (32, $M\text{-Br-Br}$), 157 (11), 153 (14), 130 (25, $M\text{-Br-COCH}_2\text{Br}$), 129 (81), 128 (56), 127 (22), 115 (20).

20 b) 4(5)-(1,2,3,4-Tetrahydronaphth-2-yl)imidazole

The mixture of 2-bromo-1-(1,2,3,4-tetrahydronaphth-2-yl)ethanone and 2-bromo-1-(2-bromo-1,2,3,4-tetrahydronaphth-2-yl)ethanone is heated with formamide as in the case of Example 4d to afford a 25 mixture of 4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole and probably both 4(5)-(1,4-dihydronaphth-2-yl)imidazole and 4(5)-(3,4-dihydronaphth-2-yl)imidazole. This mixture is directly hydrated at about 70 °C as in Example 4e to provide crude 4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole. The product as base is 30 purified by flash chromatography (solvent system: methylene chloride/methanol 9.5/0.5). M.p. of the hydrochloride salt of 4(5)-(1,2,3,4-tetrahydronaphth-2-yl)imidazole 168-177 °C.

The hydrochloride salt of 4(5)-(1,2,3,4-tetrahydronaphth-2-yl)-
35 imidazole:

MS: 198 (100, M⁺), 197 (64), 183 (31), 170 (22), 169 (30), 130 (22), 129 (18), 128 (23), 117 (16), 116 (10), 115 (30), 104 (77), 103 (23), 98 (12), 95 (12), 94 (12), 91 (16), 82 (30), 81 (15).

5

¹H NMR (80 MHz, MeOH-d₄): δ 1.66-2.46 (2H, m, -CH₂CH₂CH₂), 2.86-3.13 (5H, m, 2 x ArCH₂ and -CH₂CH₂CH₂), 7.11 (4H, s, aromatic), 7.34 (1H, m, im-5(4)), 8.85 (1H, d, ⁴J 1.54 Hz, im-2).

10

¹⁰ ¹³C NMR (20 MHz, MeOH-d₄): δ 29.23 (OFR t), 29.63 (t), 32.53 (d), 35.50 (t), 115.84 (d), 126.89 (d), 127.19 (d), 129.92 (2 d), 134.70 (d), 135.43 (s), 136.52 (s), 139.45 (s).

Example 15

15

4(5)-(2-Ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole

a) 2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester

20

1,2,3,4-Tetrahydro-2-naphthoic acid methyl ester (prepared by the methylation of 1,2,3,4-tetrahydro-2-naphthoic acid) is converted to 2-ethyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester by the procedure of Rathke, M.V. and Lindert, A. (J. Am. Chem. Soc. **93** (1971) 2318). B.p. 90-95°C/0.3 mmHg. Yield 88%.

25

1,2,3,4-Tetrahydro-2-naphthoic acid methyl ester:

¹H NMR (80 MHz, CDCl₃): δ 0.88 (3H, t, J 7.69 Hz, -CH₂CH₃), 1.53-3.34 (8H, m, -CH₂CH₃ and the methylene protons of the ring), 3.64 (3H, s, COOCH₃), 7.07 (4H, s, aromatic).

¹³C NMR (20 MHz, CDCl₃): δ 8.77 (OFR q), 26.26 (t), 30.23 (t), 31.05 (t), 36.83 (t), 46.09 (s), 51.51 (q), 125.62 (2d), 128.52 (d), 129.07 (d), 134.91 (s), 135.37 (s), 176.66 (s).

b) 2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid

The mixture of 2-ethyl-1,2,3,4-tetrahydro-2-naphthoic acid methyl ester (32.3 g), sodium hydroxide (32.3 g), ethanol 5 (450 ml) and water (323 ml) is refluxed for 8 hr. Ethanol is largely distilled in vacuo, the residue diluted with water and washed with ether. The aqueous solution gives an acidification with hydrochloric acid the desired 2-ethyl-1,2,3,4-tetrahydro-2-naphthoic acid. The product is filtered. Yield 22.2 g, 73 %.

10

2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid:

^1H NMR (80 MHz, CDCl_3): δ 0.83 (3H, t, J 7.69 Hz, $-\text{CH}_2\text{CH}_3$), 1.55-3.33 (8H, m, $-\text{CH}_2\text{CH}_3$ and the methylene protons of the 15 ring), 7.07 (3H, s, aromatic), 11.45 (1H, broad s, $-\text{COOH}$).

^{13}C NMR (20 MHz, CDCl_3): δ 8.75 (OFR q), 26.19 (t), 29.94 (t), 30.91 (t), 36.54 (t), 45.89 (s), 125.75 (2d), 128.63 (d), 129.14 (d), 134.68 (s), 135.35 (s), 183.06 (s).

20

c) 2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid chloride

A mixture of 2-ethyl-1,2,3,4-tetrahydro-2-naphthoic acid (22.0 g) and thionyl chloride is boiled for 5 days. The acid chloride is distilled. B.p. 110-115°C/0.2 mmHg. Yield 21.6 g, 90 %.

2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid chloride:

^1H NMR (80 MHz, CDCl_3): δ 0.97 (3H, t, J 7.69 Hz, $-\text{CH}_2\text{CH}_3$), 1.67-3.38 (8H, m, $-\text{CH}_2\text{CH}_3$ and the methylene protons of the ring), 7.10 (4H, s, aromatic).

¹³C NMR (20 MHz, CDCl₃): δ 8.36 (OFR q), 26.00 (t), 30.70 (t), 30.79 (t), 37.11 (t), 56.67 (s), 126.05 (d), 126.24 (d), 128.66 (d), 129.08 (d), 133.38 (s), 134.65 (s), 178.46 (s).

5 d) 1-(2-Ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone

2-Ethyl-1,2,3,4-tetrahydro-2-naphthoic acid chloride is converted to 1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone by the procedure described for example in Example 4b.

10

e) 2-Bromo-1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone

Bromination of 1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone by the procedure of Example 7d yields 2-bromo-1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone.

2-Bromo-1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone:

MS: 282 and 280 (4 and 4, M⁺), 253 and 251 (8 and 8, M-CH₂CH₃), 201 (20, M-Br), 187 (28, M-CH₂Br), 159 (22, M-COCH₂), 157 (12), 145 (30), 131 (10), 130 (12), 129 (50), 128 (32), 127 (14), 117 (100), 115 (30), 91 (21), 77 (10), 43 (24).

f) 4(5)-(2-Ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole

25

2-Bromo-1-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)ethanone is converted to 4(5)-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)-imidazole by the procedure of Example 7e. M.p. of the hydrochloride salt 148-156°C.

30

The hydrochloride salt of 4(5)-(2-ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole:

MS: 226 (63, M⁺), 211 (17, M-CH₃), 198 (25), 197 (100, M-CH₂CH₃), 195 (17), 129 (15), 128 (12), 115 (13), 104 (20), 98 (14), 82 (19), 81 (30), 69 (11).

¹H NMR (80 MHz, MeOH-d₄): δ 0.79 (3H, t, J 7.52 Hz, -CH₂CH₃), 1.63-3.34 (8H, m, -CH₂CH₃ and the methylene protons of the ring). 7.02-7.14 (5H, m, aromatic and im-4), 8.74 (1H, d, 4J 1.37 Hz, im-2).

5

¹³C NMR (20 MHz, MeOH-d₄): δ 8.48 (OFR q), 26.70 (t), 33.30 (t), 34.00 (t), 38.54 (s), 39.48 (t), 117.91 (d), 126.99 (d), 127.11 (d), 129.66 (d), 130.14 (d), 135.02 (s), 135.20 (d), 136.20 (s), 140.40 (s).

10

Example 16

4(5)-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole

15 a) cis-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid methyl ester

cis-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid methyl ester is prepared from cis-2,3-dihydro-1-methyl-1H-indene-2-carboxylic acid (see Example 4) by the standard methods using methanol and concentrated sulphuric acid. Yield 91 %.

cis-2,3-Dihydro-1-methyl-1H-indene-2-carboxylic acid methyl ester:

25

¹H NMR (80 MHz, CDCl₃): δ 1.14 (3H, d, J 6.84 Hz, CHCH₃), 2.76-3.66 (4H, m, H¹, H² and H³ of the indane ring), 3.72 (3H, s, -COOCH₃), 7.17 (4H, s, aromatic).

30 ¹³C NMR (20 MHz, CDCl₃): δ 17.01 (OFR q), 33.21 (t), 41.93 (d), 48.53 (d), 51.37 (q), 123.481 (d), 124.45 (d), 126.66 (d), 126.81 (d), 140.92 (s), 146.76 (s), 173.98 (s).

b) 2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid methyl ester

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid methyl ester is prepared by the procedure of Bathke, M.V. and Lindert, A. (J. Am. Chem. Soc. 93 (1971) 2318). B.p. 90-95°C/0.3 mmHg. Yield 51 %. The product is probably the mixture of two isomers (cis the major isomer, trans the minor isomer).

10 2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid methyl ester (the cis-isomer):

¹H NMR (80 MHz, CDCl₃): δ 0.86 (3H, t, J 7.18 Hz -CH₂CH₃), 1.122 (3H, d, J 7.18 Hz, >CHCH₃), 1.25-2.18 (2H, m, -CH₂CH₃), 3.10 (1H, q, J 7.18 Hz, >CHCH₃), AB quartet: D_A 2.82, D_B 3.52, J_{AB} 16.41 Hz (2H, H₂³ of the indane ring), 3.70 (3H, s, COOCH₃), 7.15 (4H, s, aromatic).

¹³C NMR (20 MHz, CDCl₃): δ 9.84 (OFR q), 17.53 (q), 30.76 (t), 36.99 (t), 49.77 (d), 51.28 (q), 59.27 (s), 123.60 (d), 124.60 (d), 126.45 (d), 126.63 (d), 140.74 (s), 146.52 (s), 175.52 (s).

c) 2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid

25 2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid is synthesized by the method of Example 15b. Yield 97 %.

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid (the cis-isomer):

30 ¹H NMR (80 MHz, CDCl₃): δ 0.93 (3H, t, J 7.18 Hz -CH₂CH₃), 1.23 (3H, d, J 7.18 Hz, >CHCH₃), 1.32-2.23 (2H, m, -CH₂CH₃), 3.13 (1H, q, J 7.18 Hz, >CHCH₃), AB quartet: D_A 2.83, D_B 3.49, J_{AB} 16.21 Hz (2H, H₂³ of the indane ring), 7.15 (4H, s, aromatic), 10.70 (1H, broad s, -COOH).

^{13}C NMR (20 MHz, CDCl_3): δ 9.81 (OFR q), 17.26 (q), 30.64 (t), 36.90 (t), 49.59 (d), 59.12 (s), 123.57 (d), 124.57 (d), 126.54 (d), 126.72 (d), 140.59 (s), 146.25 (s), 181.79 (s).

5 d) 2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid chloride

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid chloride is prepared by the standard method using thionyl 10 chloride and has the boiling point 105°C/0.3 mmHg. Yield 94 %.

2,3-Dihydro-2-ethyl-1-methyl-1H-indene-2-carboxylic acid chloride (the cis-isomer):

15 1_H NMR (80 MHz, CDCl_3): δ 0.95 (3H, t, J 7.18 Hz -CH₂CH₃), 1.28 (3H, d, J 7.01 Hz, >CHCH₃), 1.40-2.31 (2H, m, -CH₂CH₃), 3.18 (1H, q, J 7.01 Hz, >CHCH₃), AB quartet: D_A 2.92, D_B 3.50, J_{AB} 16.24 Hz (2H, H₂³ of the indane ring), 7.17 (4H, s, aromatic).

20

^{13}C NMR (20 MHz, CDCl_3): δ 9.38 (OFR q), 17.86 (q), 30.88 (t), 36.60 (t), 49.74 (d), 68.75 (s), 123.75 (d), 124.87 (d), 127.02 (2d), 139.07 (s), 145.61 (s), 177.21 (s).

25 e) 1-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone

1-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone is synthesized by the method of Example 4b. Yield 69 %.

30 1-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone (the cis-isomer):

¹H NMR (80 MHz, CDCl₃): δ 0.81 (3H, t, J 7.18 Hz -CH₂CH₃), 1.06 (3H, d, J 7.18 Hz, >CHCH₃), about 1.2-2.2 (2H, m, -CH₂CH₃), 2.10 (3H, s, COCH₃), 3.10 (1H, q, J 7.18 Hz, >CHCH₃), AB quartet: D_A 2.75, D_B 3.45, J_{AB} 16.41 Hz (2H, H₂³ of the indane 5 ring), 7.15 (4H, s, aromatic).

¹³C NMR (20 MHz, CDCl₃): δ 9.60 (OFR q), 17.35 (q), 27.55 (q), 29.82 (t), 35.33 (t), 49.04 (d), 64.93 (s), 123.60 (d), 124.87 (d), 126.60 (d), 126.75 (d), 140.80 (s), 146.67 (s), 210.85 (s).

10

f) 2-Bromo-1-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)-ethanone

2-Bromo-1-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)ethanone
15 is prepared from 1-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)-ethanone (21.6 g) by treatment with bromine (17.6 g) in methylene chloride (300 ml). Yield 65 %.

20

The procedure of Example 1b is used to synthesize 4(5)-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole. Yield 28 %. The base obtained is converted to its hydrochloride salt in dry ether. The hydrochloride salt is recrystallized from ethyl acetate - petroleum ether. The product is the mixture of two isomers, cis 85 % and trans 15 %. The melting point of the hydrochloride salt is 154-158°C.

The hydrochloride salt of 4(5)-(2,3-dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole (the mixture of the cis- and trans- isomer, 85 % and 15 %):

MS: 226 (30, M⁺), 211 (15, M-CH₃), 197 (100, M-CH₂CH₃), 182 (10), 129 (10), 128 (10), 115 (10), 91 (12).

¹H NMR (80 MHz, MeOH-d₄): δ 0.79 (3H, distorted t, ³J 7.35 Hz -CH₂CH₃), 0.95 (3H, d, ³J 7.18 Hz, >CHCH₃, the cis-isomer), 1.28 (d, J 7.18 Hz, >CHCH₃, the trans-isomer), 1.47-2.27 (2H, m, -CH₂CH₃), 2.99-3.48 (3H, m, H₂¹ and H₂³ protons of the indane ring). 7.14-7.31 (5H, m, aromatic and im-4(5)), 8.90 (1H, d, ⁴J 1.54 Hz, im-5).

The cis-isomer ¹³C NMR (MeOH-d₄): δ 9.72 (OFR q), 16.47 (q), 31.91 (t), 40.69 (t), 51.31 (d), 52.49 (s), 118.24 (d), 124.75 (d), 125.48 (d), 128.02 (2d), 135.08 (d), 138.83 (s), 141.10 (s), 147.70 (s).

Example 17

15 4(5)-(2,3-Dihydro-2-n-propyl-1H-inden-2-yl)imidazole

4(5)-(2,3-Dihydro-2-n-propyl-1H-inden-2-yl)imidazole is prepared according to the procedure of Example 7 using 2,3-dihydro-1H-indene-2-carboxylic acid methyl ester and n-propyl bromide as starting materials. M.p. of the hydrochloride salt: 169°-171°C.

The hydrochloride salt of 4(5)-(2,3-dihydro-2-n-propyl-1H-inden-2-yl)imidazole:

25 MS: 226 (25, M⁺), 197 (17, M-CH₂CH₃), 183 (100, M-CH₂CH₂CH₃), 115 (13), 91 (17).

¹H NMR (80 MHz, MeOH-d₄): δ 0.79-1.31 (5H, m, 0.88 distorted t, CH₂CH₃), 1.79-1.99 (2H, m, CH₂CH₂CH₃), AB quartet: D_A = D_B 30 3.23, J_{AB} 16.4 Hz (4H, H₂¹ and H₂³ of the indane ring), 7.05-7.25 (4H, m, aromatic), 7.31 (1H, d, ⁴J 1.4 Hz, im-5(4)), 8.82 (1H, d, im-2, ⁴J 1.4 Hz).

Example 18

4(5)-(2,3-Dihydro-2-n-butyl-1H-inden-2-yl)imidazole

4(5)-(2,3-Dihydro-2-n-butyl-1H-inden-2-yl)imidazole is prepared
5 according to the procedure of Example 7 using 2,3-dihydro-1H-
indene-2-carboxylic acid methyl ester and n-butyl bromide as
starting materials. M.p. of the hydrochloride salt: 129-132°C.

The hydrochloride salt of 4(5)-(2,3-dihydro-2-n-butyl-1H-inden-
10 2-yl)imidazole:

MS: 240 (22, M⁺), 197 (12, M-CH₂CH₂CH₃), 183 (100, M-CH₂CH₂CH₂-
CH₃), 170 (24), 141 (23), 129 (10), 128 (10), 115 (15), 97 (11),
91 (17), 81 (16), 77 (38), 69 (16), 57 (18), 55 (17), 51 (10).

15

¹H NMR (80 MHz, MeOH-d₄): δ 0.86 (3H, distorted t, CH₃), 1.00-
1.50 (4H, m, CH₂CH₂CH₃), 1.81-2.00 (2H, m, CH₂CH₂CH₂CH₃), AB
quartet: D_A = D_B 3.23, J_{AB} 16.4 Hz (4H, H₂¹ and H₂³
protons of the indane ring), 7.05-7.25 (4H, m, aromatic), 7.31
20 (1H, d, ⁴J 1.4 Hz, im-5(4)), 8.81 (1H, d, ⁴J 1.4 Hz, im-2).

Example 19

4(5)-(2,3-Dihydro-2-ethyl-1-hydroxy-1H-inden-2-yl)imidazole

a) 4(5)-(2,3-Dihydro-2-ethyl-1-oxo-1H-inden-2-yl)imidazole

- 5 2-Acetyl-1-indanone (Liebigs Ann. Chem. 347 (1906) 112) is alkylated with ethylbromide in acetone in the presence of sodiumcarbonate to 2-acetyl-2-ethyl-1-indanone. The acetyl group is brominated with bromine in methanol and to imidazole by heating in formamide as before. The melting point of the product as base is 126-127°C (from ethyl
10 acetate).

b) 4(5)-2,3-Dihydro-2-ethyl-1-hydroxy-1H-inden-2-yl)imidazole

The carbonyl group of oxo inden imidazole from the step a) is reduced
15 to the alcohol group with sodium borohydride in ethanol. The product is the mixture of cis-trans stereoisomers, the purification of which is accomplished by liquid chromatography.

cis-isomer as hydrochloride (m.p. 184-185°C):

20 ^1H NMR (80 MHz, MeOH-d₄): 0.73 (3H, t), 1.86 (2H, m), 3.36 (2H, m), 3.61 (3H, s), 5.15 (1H, s), 7.06 (1H, d), 7.2-7.4 (4H, m), 8.69 (1H, d)

trans-isomer as hydrochloride:

25 ^1H NMR (80 MHz, MeOH-d₄): 0.80 (3H, t), 1.84 (2H, m), 3.15 (2H, m), 3.24 (3H, s), 5.15 (1H, s), 6.87 (1H, d), 7.2-7.4 (4H, m), 8.54 (1H, d)


Example 20

4(5)-(2,3-Dihydro-2-ethyl-1H-inden-2-yl)-imidazole

The oxo derivative prepared in the example 19 (step a) or the hydroxy derivative (step b) is hydrogenated in 2 N hydrochloric acid in the presence of 10% palladium on carbon at 70°C. When the uptake of hydrogen ceases, the reaction mixture is filtered and made alkaline. The product is extracted with methylene chloride which is washed with water, dried and evaporated to dryness. From the residue, which is the product as base, is made the hydrochloride using dry hydrogen chloride in ethyl acetate. It has M.p.: 211-215°C.

CLAIMS

1. Substituted imidazoles of the formula



and their non-toxic acid addition salts, wherein X is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{O}-$, R_1 is H, alkyl of 1 to 4 carbon atoms, alkenyl of 2 to 4 carbon atoms, OCH_3 , or OCH_2CH_3 ; R_2 is H, CH_3 , CH_2CH_3 , OCH_3 or OH, R_3 is H, CH_3 , CH_2CH_3 , OCH_3 or Hal and R_4 is H, CH_3 , CH_2CH_3 , OCH_3 or Hal, and Hal is halogen.

2. Substituted imidazoles according to claim 1
10 wherein X is $-\text{CH}_2-$.

3. Substituted imidazoles according to claim 1
wherein X is $-\text{CH}_2\text{CH}_2-$.

4. Substituted imidazoles according to claim 1
wherein X is $-\text{O}-$.

15 5. Substituted imidazole according to claim 1
wherein R_1 is hydrogen, CH_3 , CH_2CH_3 , OCH_3 , OCH_2CH_3 .

6. Substituted imidazole according to claim 1
wherein R_1 is hydrogen, CH_3 , CH_2CH_3 , OCH_3 , OCH_2CH_3 and X
is CH_2 .

20 7. Substituted imidazoles according to claim 1,

wherein R₁ is hydrogen, CH₃, CH₂CH₃, OCH₃, OCH₂CH₃ and X is CH₂ and R₂, R₃ and R₄ are hydrogen.

8. 4(5)-(2,3-Dihydro-1H-inden-2-yl)imidazole.

9. 4(5)-(2,3-Dihydrobenzofuran-2-yl)imidazole.

5 10. 4(5)-(5-Bromo-2,3-dihydrobenzofuran-2-yl)imidazole

11. 4(5)-(2,3-Dihydro-2-ethyl-5-methyl-1H-inden-2-yl)imidazole

12. 4(5)-(2-Ethyl-1,2,3,4-tetrahydronaphth-2-yl)imidazole

13. 4(5)-(2,3-Dihydro-2-ethyl-1-methyl-1H-inden-2-yl)imidazole

14. 4(5)-(2,3-Dihydro-2-n-propyl-1H-inden-2-yl)imidazole

10 15. 4(5)-(2,3-Dihydro-4-methyl-1H-inden-2-yl)imidazole

16. 4(5)-(2,3-Dihydro-5-methyl-1H-inden-2-yl)imidazole

17. 4(5)-(2,3-Dihydro-1-methyl-1H-inden-2-yl)imidazole

18. 4(5)-(2,3-Dihydro-1,4-dimethyl-1H-inden-2-yl)imidazole

19. 4(5)-(2,3-Dihydro-1,6-dimethyl-1H-inden-2-yl)imidazole

15 20. 4(5)-(5-Chloro-2,3-dihydro-1H-inden-2-yl)imidazole

21. 4(5)-(5-Bromo-2,3-dihydro-1H-inden-2-yl)imidazole

22. 4(5)-(2,3-Dihydro-1-hydroxy-1H-inden-2-yl)imidazole

23. 4(5)-(2,3-Dihydro-2-methyl-1H-inden-2-yl)imidazole

24. 4(5)-(4-Chloro-2,3-dihydro-1H-inden-2-yl)imidazole

25. 4(5)-(4-Bromo-2,3-dihydro-1H-inden-2-yl)imidazole

26. 4(5)-(2,3-Dihydro-2-ethyl-1H-inden-2-yl)imidazole

27. 4(5)-(2,3-Dihydro-2-n-butyl-1H-inden-2-yl)imidazole

28. 4(5)-(2,3-Dihydro-2,5-dimethyl-1H-inden-2-yl)imidazole


5 29. 4(5)-(1,2,3,4-Tetrahydronaphth-2-yl)imidazole

30. 4(5)-(2,3-Dihydro-2-ethyl-1-hydroxy-1H-inden-2-yl)imidazole.

31. A process for the preparation of an imidazole as claimed in claim 1, which comprises:


a) halogenating a compound of formula

10




wherein R₂, R₃ and R₄ are as defined in claim 1 to give a product of the formula

15




wherein Hal is Cl or Br

b) reacting the said product with formamide to give a compound of formula




c) which is then hydrogenated catalytically to give a compound as claimed in claim 1, wherein R₁ is hydrogen and R₃ and R₄ as defined in claim 1 and R₂ is hydrogen, methyl or ethyl.

5 32. A process for the preparation of a compound as claimed in claim 1, which comprises reacting a compound of formula




wherein R₅, R₆ R₇ and R₈ are each hydrogen, hydroxy, 10 halogen, amino, -O-alkyl containing 1 to 7 carbon atoms, or




(wherein R₉ is alkyl of 1 to 7 carbon atoms or aryl of 6 to 10 carbon atoms); and wherein R₅ and R₇ can be combined to form a keto group, or R₆ and R₈ can be combined to form a 15 keto group, with formamide to give a compound of formula (I) as defined in claim 1.

33. A process for the preparation of a compound as claimed in claim 1, which comprises:
halogenating a compound of formula




to give a compound as defined in claim 1, wherein R₃ is a halogen and R₄ is H or both R₃ and R₄ are halogen atoms.


34. A process for the preparation of a compound as claimed in claim 1, which comprises brominating a 5 compound of formula



to give a compound of formula




which is reacted with formamide to produce a compound of 10 formula



which is hydrogenated to give a compound of formula (I), wherein R₁ is hydrogen, R₃, R₄ and X are as defined in claim 1 and R₂ is hydrogen, methyl or ethyl.


15 35. A process for the preparation of a compound as claimed in claim 1, which comprises reacting a compound of the formula

- 58 -




wherein R is a benzyl group

with thionyl chloride to give a compound of formula:




5 which is reacted with sodium cyanide to give a compound of formula:




which is hydrolysed in alkaline solution to give a compound of formula:

10




which is reacted with polyphosphoric acid to give a compound of formula:




which is either

- (a) hydrogenated in the presence of palladium on carbon as catalyst to give a compound of formula:


5




which is reduced with NaBH_4 to give a compound of formula:



or (b) reduced with NaBH_4 to give a compound of formula:



- 10 which is hydrogenated in the presence of palladium on carbon to give a compound of formula:




- 60 -

36. A pharmaceutical composition comprising a substituted imidazole as claimed in any one of claims 1 to 30 in association with a compatible, pharmaceutically acceptable carrier.

5 37. An imidazole derivative as claimed in any one of claims 1 to 30 or a non-toxic acid addition salt for use in therapy as an α_2 -receptor antagonist.


CLAIMS FOR THE DESIGNATED STATE AT

1. A process for the preparation of a substituted imidazole of the formula




and its non-toxic acid addition salts, wherein


X is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$ or $-\text{O}-$, R₁ is H, alkyl of 1-4 carbon atoms, alkenyl of 2 to 4 carbons atoms, OCH₃ or OCH₂CH₃, R₂ is H, CH₃, CH₂CH₃, OCH₃ or OH, R₃ is H, CH₃, CH₂CH₃, OCH₃ or Hal, R₄ is H, CH₃, CH₂CH₃, OCH₃ or Hal, and Hal is halogen which comprises halogenating a compound of formula



wherein R₂, R₃ and R₄ are as defined above, to give a product of formula




wherein Hal is Cl or Br, reacting the said product with formamide to give a compound of formula




and hydrogenating the latter catalytically to give a compound of formula (I), wherein R₁ is hydrogen, R₃ and R₄ are as defined above, and R₂ is hydrogen, methyl or ethyl.

2. A process for the preparation of a compound of formula I as defined in claim 1 which comprises reacting a compound of formula




wherein R₅, R₆, R₇ and R₈ are each hydrogen, hydroxy, halogen, amino, -O-alkyl containing 1 to 7 carbon atoms, or




(wherein R₉ is alkyl of 1 to 7 carbon atoms or aryl of 6 to 10 carbon atoms); and wherein R₅ and R₇ can be combined to form a keto group, or R₆ and R₈ can be combined to form a keto group, with formamide to give a compound of formula (I) as defined in claim 1.

3. A process for the preparation of a compound of formula I as defined in claim 1 which comprises halogenating a compound of formula




to give a compound of formula I as defined in claim 1, wherein R₃ is a halogen and R₄ is H or both R₃ and R₄ are halogen atoms.


4. A process for the preparation of a compound of formula I as defined in claim 1 which comprises brominating a compound of formula



to give a compound of the formula




which is reacted with formamide to produce a compound of formula




which is hydrogenated to give a compound as claimed in claim 1 wherein R₁ is hydrogen, R₃, R₄ and X are as defined above and R₂ is hydrogen, methyl or ethyl.


5. A process in the preparation of a compound of formula I as defined in claim 1 which comprises reacting a compound of formula




wherein R is a benzyl group, with thionyl chloride to give a compound of formula:




which is reacted with sodium cyanide to give a compound of formula:



which is hydrolysed in alkaline solution to give a compound of formula:




which is reacted with polyphosphoric acid to give a compound of formula:




which is either


- a) hydrogenated in the presence of palladium on carbon as catalyst to give a compound of formula:




which is reduced with NaBH_4 to give a compound of formula:




or (b) reduced with NaBH_4 to give a compound of formula:




which is hydrogenated in the presence of palladium on carbon to give a compound of formula:




6. A process for the preparation of a compound of formula 1 as defined in claim 1 which comprises halogenating and reacting with formamide a compound of the formula




to give a compound of the formula



which is either (a) hydrogenated in the presence of palladium on carbon to give a compound of formula




or (b) reacted with NaBH4 to give a product of formula




and then


hydrogenated in the presence of palladium on carbon to give a compound of the formula




7. A process for the preparation of a compound of formula 1 as defined in claim 1 which comprises halogenating and reacting with formamide a compound of the formula



to give a compound of the formula



which is hydrogenated with Pd/C to give a compound of formula



8. A process as claimed in any one of claims 1 to 7 in which the product obtained is converted into a non-toxic acid addition salt.



European Patent
Office

EUROPEAN SEARCH REPORT

0183492
APPLICATION NUMBER

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 85308491.1																					
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)																					
A	<u>DE - A1 - 3 324 069</u> (FARMITALIA) * Formula I; claim 12 * --	1, 36	C 07 D 233/58 C 07 D 405/04 A 61 K 31/415																					
A	<u>FR - A1 - 2 542 738</u> (SYNTHELABO) * Claims 1,3 * --	1, 36, 37																						
A	<u>DE - A1 - 2 933 962</u> (HOECHST) * Examples 16,17 * --	1																						
A	CHEMICAL ABSTRACTS, vol. 101, no. 3, July 16, 1984, Columbus, Ohio, USA CHAPLEO, CHRISTOPHER B.; MYERS, PETER L.; BUTLER, RICHARD C.M.; DAVIS, JOHN A.; DOXEY, JOHN C.; HIGGINS, STANLEY D.; MYERS, MALCOLM; ROACH, ALAN G.; SMITH, COLIN F.C.; et al. "α-Adrenoceptor reagents. 2. Effects of modification of the 1,4-benzodioxan ring system on α-adrenoreceptor activity." page 18, column 2, abstract no. 16791y & J.Med.Chem. 1984, 27(5), 570-6 -----	1																						
TECHNICAL FIELDS SEARCHED (Int. Cl. 4)																								
C 07 D 233/00 C 07 D 405/00																								
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search VIENNA</td> <td>Date of completion of the search 17-02-1986</td> <td>Examiner HAMMER</td> </tr> <tr> <td colspan="3">CATEGORY OF CITED DOCUMENTS</td> </tr> <tr> <td>X : particularly relevant if taken alone</td> <td colspan="2">T : theory or principle underlying the invention</td> </tr> <tr> <td>Y : particularly relevant if combined with another document of the same category</td> <td colspan="2">E : earlier patent document, but published on, or after the filing date</td> </tr> <tr> <td>A : technological background</td> <td colspan="2">D : document cited in the application</td> </tr> <tr> <td>O : non-written disclosure</td> <td colspan="2">L : document cited for other reasons</td> </tr> <tr> <td>P : intermediate document</td> <td colspan="2">& : member of the same patent family, corresponding document</td> </tr> </table>				Place of search VIENNA	Date of completion of the search 17-02-1986	Examiner HAMMER	CATEGORY OF CITED DOCUMENTS			X : particularly relevant if taken alone	T : theory or principle underlying the invention		Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		A : technological background	D : document cited in the application		O : non-written disclosure	L : document cited for other reasons		P : intermediate document	& : member of the same patent family, corresponding document	
Place of search VIENNA	Date of completion of the search 17-02-1986	Examiner HAMMER																						
CATEGORY OF CITED DOCUMENTS																								
X : particularly relevant if taken alone	T : theory or principle underlying the invention																							
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date																							
A : technological background	D : document cited in the application																							
O : non-written disclosure	L : document cited for other reasons																							
P : intermediate document	& : member of the same patent family, corresponding document																							